MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors

Post-transcriptional regulation of O6-methylguanine-DNA methyltransferase MGMT in glioblastomas

(2017) Valya Ramakrishnan et al.   Cancer Biomarkers

O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents

(2015) T Walter et al.   BRITISH JOURNAL OF CANCER

Prognostic and Predictive Roles of MGMT Protein Expression and Promoter Methylation in Sporadic Pancreatic Neuroendocrine Neoplasms

(2014) Anja Maria Schmitt et al.   NEUROENDOCRINOLOGY

In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing

(2013) Simone Kreth et al.   ACTA NEUROPATHOLOGICA

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience

(2013) Robert L. Fine et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status

(2012) Pierre Bady et al.   ACTA NEUROPATHOLOGICA

Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, methylight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 g

(2012) Véronique Quillien et al.   CANCER

Inhibition of Histone Deacetylation Potentiates the Evolution of Acquired Temozolomide Resistance Linked to MGMT Upregulation in Glioblastoma Xenografts

(2012) G. J. Kitange et al.   CLINICAL CANCER RESEARCH

Prospective Study of Bevacizumab Plus Temozolomide in Patients With Advanced Neuroendocrine Tumors

(2012) Jennifer A. Chan et al.   JOURNAL OF CLINICAL ONCOLOGY

STAT3 Inhibition Overcomes Temozolomide Resistance in Glioblastoma by Downregulating MGMT Expression

(2012) Shinji Kohsaka et al.   MOLECULAR CANCER THERAPEUTICS

miR-181d: a predictive glioblastoma biomarker that downregulates MGMT expression

(2012) W. Zhang et al.   NEURO-ONCOLOGY

ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary

(2012) Marianne Pavel et al.   NEUROENDOCRINOLOGY

Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma

(2012) Arne Christians et al.   PLoS One

Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas

(2012) Ingrid H. Olsen et al.   TheScientificWorldJOURNAL

Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy

(2011) Staffan Welin et al.   CANCER

Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma

(2011) Miyuki Uno et al.   Clinics

Temozolomide: Mechanisms of Action, Repair and Resistance

(2011) Jihong Zhang et al.   Current Molecular Pharmacology

First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

(2010) Jonathan R. Strosberg et al.   CANCER

Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma

(2009) Cosimo Durante et al.   ENDOCRINE-RELATED CANCER

Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods

(2009) Lucie Karayan-Tapon et al.   JOURNAL OF NEURO-ONCOLOGY

O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors

(2008) M. H. Kulke et al.   CLINICAL CANCER RESEARCH

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER